NCT04850339View on ClinicalTrials.gov

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

October 27, 2021

Study Completion Date

October 27, 2021

Conditions
Healthy
Interventions
BIOLOGICAL

ANXV

Intravenous infusion

OTHER

Placebo

Intravenous infusion

Trial Locations (1)

9713

QPS Netherlands B.V., Groningen

Sponsors
All Listed Sponsors
lead

Annexin Pharmaceuticals AB

INDUSTRY

NCT04850339 - First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers | Biotech Hunter | Biotech Hunter